No Data
No Data
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation
ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8%
ImpediMed (ASX:IPD) recorded revenue of AU$2.6 million for the third quarter of fiscal 2024, up from AU$2.3 million for the prior three-month period, according to a Tuesday filing with the Australian
Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant
Medical technology company Impedimed (ASX:IPD) has made organizational changes as part of measures to reduce operating costs by 10% to 15% by the end of 2024, according to a Wednesday Australian bours
Ord Minnett Starts ImpediMed at Speculative Buy, Price Target Is AU$0.16
07:55 PM EDT, 04/16/2024 (MT Newswires) -- Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16
ImpediMed Initiated at Speculative Buy by Ord Minnett
ImpediMed Initiated at Speculative Buy by Ord Minnett
ImpediMed's (ASX:IPD) Investors Will Be Pleased With Their Notable 72% Return Over the Last Year
No Data